Stereotactic Radiosurgery

Stereotactic Radiosurgery for Intracranial Tumors: Puerto Rico Experience

David Lozada, MD*; Ricardo H. Brau, MD†

Historically, the treatment for most intracranial pathologies has included medical management, surgery, radiotherapy and recently, stereotactic radiosurgery. Since its introduction, stereotactic radiosurgery has evolved from an investigational concept into a recognized neurosurgical procedure for the management of a wide variety of brain disorders. The goal of this research was to describe the experience in Puerto Rico using this technology and review the efficacy, safety, and role of radiosurgery in the treatment of the most common intracranial tumors treated today. Patients treated from 1999-2009 at Clínicas Las Américas were reviewed and medical literature databases were searched for articles pertaining to stereotactic radiosurgery performed in these intracranial tumor pathologies: meningiomas, gliomas, cerebral metastasis, vestibular schwannomas and pituitary adenomas. Each study was examined to determine the radiosurgical parameters, duration of follow-up review, tumor growth control rate and complications. A total of 50 peer-reviewed studies were examined. Radiosurgery in benign tumors resulted in the control of tumor size in 90% of treated patients. Unfortunately radiosurgery for malignant tumors is not curative, but has been effective in improving survival and quality of life. Although microsurgery remains the primary treatment modality in most cases, stereotactic radiosurgery offers both safe and effective treatment for much intracranial pathologies. Further refinements in the radiosurgical technique will likely lead to improved outcomes and make it a standard of care. [PR Health Sci J 2010;3:286-292]

Key words: Stereotactic radiosurgery, Intracranial tumors, Linear accelerator, Gamma Knife Surgery

Stereotactic Radiosurgery (SRS) is a technology that utilizes externally generated ionizing radiation to inactivate or eradicate (a) defined target(s) in the head or spine without the need to make an incision. The target is defined by high-resolution stereotactic imaging. It uses multiple convergent beams aimed to the target. The beams deliver a maximal dose to the target (with precision of approximately 1mm), while minimizing irradiation of the surrounding tissues. All the treatment is performed in a single session. The procedure requires a multidisciplinary team consisting of a neurosurgeon, radiation oncologist and medical physicist. Technologies that are used to perform SRS include linear accelerators, particle beam accelerators and multisource Cobalt 60 units. In order to enhance precision, various devices may incorporate robotics and real time digital imaging (Stereotactic Radiosurgery Task Force AANS/CNS/ASTRO, March 20, 2006).

“Stereotactic radiosurgery” was invented by the Swedish neurosurgeon Lars Leksell in 1951. Since its introduction, stereotactic radiosurgery (SRS) has evolved from an investigational concept into a recognized neurosurgical procedure for the management of a wide variety of brain disorders. Presently, radiosurgery can be employed either as a definitive or adjuvant treatment modality in the fields of neuro-oncology, cerebrovascular and functional neurosurgery.

The three major sources of radiation used today to perform SRS are the multi-source Cobalt 60 units, linear accelerators and the particle beam accelerators. These machines provide extremely accurate targeting and precise treatment for brain cancers. They are dedicated to treat brain tumors and other cerebral conditions in a one-day treatment. The original system is the Gamma Knife® (GK). Its Clinical efficacy has been well documented, with more than 502,726 cases treated worldwide.

* Resident PGY-4, †Chairman and Professor of the Section of Neurological Surgery University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

The authors have no conflict of interest to disclose.

Address correspondence to: Ricardo H. Brau MD, Professor and Chairman, Section of Neurosurgery University of Puerto Rico Medical Sciences Campus / Section of Neurosurgery PO Box 365067, San Juan, Puerto Rico 00936. Tel: (787) 765-8276

* Email: rhbrau@gmail.com
providing the data for over 2,500 publications in peer-reviewed medical literature. The GKs is ideal for tumors less than 3.5 cm, and functional disorders of the brain.

The linear accelerator based radiosurgery machines are also prevalent throughout the world. One benefit of this technology is its ability to easily treat large tumor volumes (over 3.5 cm) by treating over several sessions. Most linear accelerator based machines are used for general radiotherapy, however with special adapters they can be used for Stereotactic Radiosurgery. Here in Puerto Rico, at “Clínica Las Américas” there is a linear accelerator-based system. The initial radiosurgery system at Clínicas Las Américas installed in 1999 was manufactured by Radionics®. In 2003 this system was changed to a Brain Lab System® that incorporated a multileaf collimator. The linear accelerator systems utilize radiation beams that are redirected in many “arcs” to lessen the adverse effects on healthy tissue. These machines can perform radiosurgery on tumors smaller than 3.5cm with the same precision of a Gamma Knife and for larger tumors it can fractionate treatments over several days.

In contrast to traditional radiosurgery, the CyberKnife® Robotic Radiosurgery System takes advantage of intelligent robotics to enable the effective treatment of tumors anywhere in the body. It utilizes a 6 MV compact linear accelerator mounted on a computer-controlled six-axis robotic manipulator that permits a wide range of beam orientations. To date, an estimated over 80,000 patients have been treated with the CyberKnife® System and currently more than 50 percent of all CyberKnife® procedures in the United States are extra cranial.

The particle/proton beam exists in a handful of centers in the United States. Due to the cost of the particle beam facility, little research is currently available; however, more is expected in the future.

Procedure

At Clínicas Las Américas all radiosurgical procedures are performed on an outpatient basis. The patient is referred to the neurosurgical and radio-oncology clinic, where a detailed history and physical examination is performed. The patients are presented with an in depth review of the treatment options. If radiosurgery is deemed appropriate, the patient is sent to the radiology department where a volumetric MR imaging study is obtained. On the day of treatment a stereotactic head ring is applied after administration of a local anesthetic agent. Subsequently, stereotactic CT scanning is performed. One to three-millimeter thick slices are obtained throughout the entire head. The volumetric MR imaging study obtained is used to generate a “preplan. The stereotactic CT scan and MR images are transferred to the treatment-planning computer. The CT scan and MR images are fused electronically. The preplan is carefully examined and adjusted to generate the actual treatment plan.

The patient is treated accordingly. The head ring is removed on the same day of treatment. After a short observation period, the patient is discharged. If the patient is treated with fractionated radiosurgery the ring is removed after the last treatment section. Normally the fractions are given in 3 days or less. Close clinical and radiological neuroimaging follow-up examination is arranged at appropriate intervals depending on the entity treated and the condition of the patient.

Applications of Stereotactic Radiosurgery

The most common applications of stereotactic radiosurgery include treatment of intracranial malignant tumors, benign intracranial tumors, intracranial vascular disorders, and functional disorders (Figure 1). SRS is also being developed for treatment of extra cranial sites including lung tumors, liver tumors, and spinal lesions.

From February 17, 1999 to December 31, 2009 seven hundred and sixty nine (769) patients have undergone stereotactic radiosurgery at “Clínica Las Américas in San Juan, PR” (Table 1). Within the benign intracranial tumors, meningiomas, pituitary adenomas and acoustic neuromas are the most common intracranial pathologies treated by SRS in Puerto Rico (Figure 2). Among these benign tumors, meningiomas are the most predominant. In the category of intracranial malignant tumors, secondary cerebral metastasis and primary malignant glial tumors are the most commonly treated pathologies by SRS (Figure 3). Among these intracranial malignant tumors, secondary cerebral metastases make up the largest volume due to their frequent incidence.

Detailed analysis of different segments of the treated pathological entities at Clínicas Las Américas will be submitted for publication in the near future.
pathologies: meningiomas, gliomas, cerebral metastasis, vestibular schwannomas, and pituitary adenomas. Each study reviewed and analyzed has an update of the current indications, limitations, safety and outcomes of this technology. A total of 50 published studies were reviewed.

Benign Intracranial Tumors

Meningiomas

Meningiomas are the most important type of intracranial mesodermal tumors and represent approximately 18% of all primary intracranial tumors. To date over 169 (42% of the benign intracranial tumors) cases have been treated in Puerto Rico. Histologically, the WHO 2007 Classification of Meningiomas recognizes several meningioma subtypes of which nine are considered benign (WHO Grade I).

In the 1990s stereotactic radiosurgery was described for the first time in the treatment of meningiomas and opened up new ways to treat these tumors. Even though radiation treatment of meningiomas was initially controversial it became more and more accepted after studies provided evidence that radiation could be an effective treatment (1-2).

Surgery, however, is still considered the gold standard (3-4) because it is the most effective way to reduce tumor volume instantly, decompress brain tissue and provide tissue diagnosis. Although surgery of convexity meningiomas usually cures the patient, this is often not possible in the skull base. Depending on the Simpson grade (Table 2) of tumor removal, 5-year recurrence rates are found to be 9% for Grade I, between 19 and 29% for Grade II and III, and 44% for Grade IV tumor resection.5,6 The 10-year survival rate reported in the literature was 75% but could be as low as 39% if less than a gross-total resection was achieved.7 Because in skull base tumors incomplete removal is described in more than 40% of cases (8-9) radiosurgery plays an important role as a complementary treatment option to achieve a tumor growth stabilization.

Table 1. Cumulative indications treated at Clinicas Las Americas in San Juan, P.R. (1999-2009).

<table>
<thead>
<tr>
<th>Benign Tumors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vestibular Schwannoma</td>
<td>78</td>
</tr>
<tr>
<td>Trigeminal Schwannoma</td>
<td>6</td>
</tr>
<tr>
<td>Other Schwannoma</td>
<td>5</td>
</tr>
<tr>
<td>Gliomas Grade I</td>
<td>6</td>
</tr>
<tr>
<td>Meningioma</td>
<td>169</td>
</tr>
<tr>
<td>Pituitary Adenoma (Secreting)</td>
<td>25</td>
</tr>
<tr>
<td>Pituitary Adenoma (Non-Secreting)</td>
<td>42</td>
</tr>
<tr>
<td>Pineal Region Tumor</td>
<td>1</td>
</tr>
<tr>
<td>Hemangioblastoma</td>
<td>2</td>
</tr>
<tr>
<td>Cranial Hypophyseoma</td>
<td>1</td>
</tr>
<tr>
<td>Glomus Tumor</td>
<td>5</td>
</tr>
<tr>
<td>Other Benign Tumors</td>
<td>43</td>
</tr>
<tr>
<td>Total</td>
<td>383</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Malignant Tumors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant Gliomas Tumor (II, III, IV)</td>
<td>60</td>
</tr>
<tr>
<td>Metastatic Tumor</td>
<td>192</td>
</tr>
<tr>
<td>Oligodendrogiomas</td>
<td>5</td>
</tr>
<tr>
<td>Hemangioendothelioma</td>
<td>1</td>
</tr>
<tr>
<td>Other Malignant Tumors</td>
<td>16</td>
</tr>
<tr>
<td>Total</td>
<td>274</td>
</tr>
<tr>
<td>Total Tumors</td>
<td>657</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vascular Disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AVM's</td>
<td>91</td>
</tr>
<tr>
<td>Cavernous Angioma</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Functional Disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Trigeminal Neuralgia</td>
<td>18</td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
</tr>
</tbody>
</table>

| Total Indications                  | 769|

Figure 2. Pie graph depicting the most common intracranial benign tumors treated with stereotactic radiosurgery in Puerto Rico. Statistics adapted from Clínica Las Américas in San Juan, PR (1999-2009).

Figure 3. Pie graph depicting the most common intracranial malignant tumors treated with stereotactic radiosurgery in Puerto Rico. Statistics adapted from Clínica Las Américas in San Juan, PR (1999-2009).
Stereotactic Radiosurgery

Table 2. Table showing the Simpson grading system used for the removal of meningiomas.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Degree of removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Macroscopically complete removal with excision of dural attachment and abnormal bone (including sinus resection when involved)</td>
</tr>
<tr>
<td>II</td>
<td>Macroscopically complete with endothermy coagulation (Bovie, or laser) of dural attachment</td>
</tr>
<tr>
<td>III</td>
<td>Macroscopically complete without resection or coagulation of dural attachment or of its extradural extensions (e.g. hyperostotic bone)</td>
</tr>
<tr>
<td>IV</td>
<td>Partial removal leaving tumor in situ</td>
</tr>
<tr>
<td>V</td>
<td>Simple decompression (±biopsy)</td>
</tr>
</tbody>
</table>

In a paper on patients with benign meningiomas, Kondziolka, et al., (10) reported that 91% remained neurologically stable at 5- to 10-year follow-up after radiosurgery. Tumor control rates have ranged from 84 to 100% after either gamma knife surgery or linear accelerator based radiosurgery. Based on a large number of studies (11-18) and a recent study of Guenther CF et al., tumor control with radiosurgery is expected in more than 90% of patients with WHO Grade I and II meningiomas. Radiosurgery is capable of more than just controlling tumor growth. It has been documented that in 82.3% of all tumors treated with radiosurgery achieved a significant reduction in tumor volume.

The best chance to cure patients with meningiomas is to perform a total surgical removal of the tumor and its attachment (11). Microsurgery strives for total tumor resection with preservation of all nervous and vascular structures. Complementary Radiosurgery should be considered to treat any remnant tumor left after surgery. Also can be use as a primary line of treatment if the morbidity and mortality of meningioma resection are considered unacceptable.

Vestibular Schwannomas

Among benign intracranial tumors, Vestibular Schwannomas (VS) has, to date, been the second most frequent target for stereotactic radiosurgery (World Wide Statistics Leksell GK Society 2009). This benign lesion (representing approximately 10% of all primary brain tumors) is a neoplastic proliferation of Schwann cells arising from the myelin sheath of the vestibular branches of the eighth cranial nerve. These tumors are slightly more common in women, present at a mean age of 50 years, and occur bilaterally in patients with Neurofibromatosis type II. In Puerto Rico, 78 cases of acoustic schwannomas (19% of benign intracranial tumors) have been treated at “Clínicas Las Américas” with good results and low complications.

Surgical resection of the tumor is indicated for patients with larger tumors (>3 cm). These tumors can produce major neurological deficits from brainstem or cranial nerve compression. Stereotactic radiosurgery is recommended for small or medium-sized tumors (<3 cm) with the goals of preserving neurological function, prevention of tumor growth and in many cases a reduction in the tumor volume. Some physicians advocate radiosurgery in patients unwilling or unable to undergo microsurgery, whereas others advocate its use in those with postoperative residual or recurrent tumor. Wallner et al. (19), published that external-beam radiation lowered the postoperative recurrence rate from 46 to 6% in a surgical series at the University of California, San Francisco.

Experience with radiosurgery now extends to over thirty years. Single fraction Radiosurgery has good useful hearing preservation rates (70–71%), but fractioned radiotherapy with LINAC or Cyber knife are providing even better results (74–98% useful hearing preservation) (20-21). Proton Beam did not provide good results for preservation of hearing (33%) (22).

Recently Pollock et al. (23) designed a prospective observational study comparing adult patients with unilateral, unoperated VS less than 3 cm in diameter who underwent surgical resection or radiosurgery. Early outcomes were better for VS patients undergoing stereotactic radiosurgery compared with surgical resection (Level 2 evidence). With the current available results, radiosurgery should be considered the best management strategy for the majority of VS patients.

Pituitary Adenomas

Pituitary adenomas are very common lesions, constituting between 10 and 20% of all primary brain tumors (24-25). Pituitary adenomas are broadly classified into two groups; tumors that secrete excessive amounts of normal pituitary hormones and non-secreting tumors. The most common of the secreting tumors is the prolactinoma. Fortunately, many prolactinomas can usually be managed medically with dopamine agonist drugs. The second most common functioning pituitary adenoma is the Growth Hormone-secreting tumor (producing Acromegaly), followed by tumors that secrete ACTH (Cushing disease).

The second group of pituitary adenomas is composed of tumors that do not secrete any known biologically active pituitary hormones, and these represent approximately 30% of all pituitary tumors (26). Non-functioning pituitary tumors may cause symptoms related to a mass effect, usually compressing the optic chiasm or invading the cavernous sinus. Those patients harboring nonfunctioning adenomas can also have hypopituitarism as a result of compression of the normal functioning pituitary gland. For both types of pituitary adenomas, a recurrent tumor growth resulting from residual tumor invasion into surrounding cavernous sinus or incomplete tumor resection is quite common (27).

Microsurgery is the gold standard for treatment of sellar tumors. It offers the advantages of pathological confirmation, reduction of tumor volume with immediate decompression of the optic apparatus, and rapid reduction of hormone over-secretion. Transsphenoidal resection is currently the
Stereotactic Radiosurgery

most widely used approach for pituitary adenomas, but the transcranial approach remains a viable alternative for sellar lesions with extensive supra- or parasellar extension. Even in the best of hands, however, microsurgery alone provides long-term tumor control rates of 50 to 80% (28-29).

Stereotactic radiosurgery is typically employed after surgery, but in selected cases may be employed as the primary treatment. It may serve as a primary treatment for those patients deemed unfit for microsurgical tumor removal because they have other comorbidities or demonstrable tumors in a surgically inaccessible location.

Stereotactic radiosurgery has been performed in more 67% (17% of benign tumors treated; 25% secreting and 42% non-secreting) cases in Puerto Rico to control tumor growth and normalize hormone production from pituitary adenomas. At the same time, great attention and effort in the field of stereotactic radiosurgery have been placed on the function preservation of surrounding neuronal, vascular, and hormone producing structures.

In most series tumor control is defined as either an unchanged or decreased volume on follow-up neuroimaging studies. In nearly all published series, stereotactic radiosurgery afforded excellent control of tumor growth (27-35). In these studies, the tumor control rates varied from 83 to 100% (28, 33-39).

More recently, stereotactic radiosurgery has been demonstrated to be a safe and highly effective treatment for patients with recurrent or residual pituitary adenomas (40).

Malignant Intracranial Tumors

Brain Metastasis

Intracranial metastases have been considered ideal targets for radiosurgery and stereotactic radiotherapy due to their small spherical size, frequently non-infiltrative borders, and in many instances located in non-eloquent areas of the brain. Brain metastases incidence is very high, seen in 25% to 30% of all malignant tumors treated. In the United States. In Puerto Rico malignant gliomas account for 14% of all primary brain tumors diagnosed annually (46). Forty four thousand primary brain tumors are pathologically and clinically distinct from grade I lesions and should be considered potentially malignant. High grade gliomas grow much more quickly, and are assigned either a grade III (anaplastic) or IV (glioblastoma multiforme). Combined, grade III and IV gliomas account for approximately 40% of all primary brain tumors in patients aged 40-49 years, and 60% in patients older than 60 years. In most clinical series, grade III tumors represent approximately 10-15% of gliomas and grade IV constituting at least 30% of all primary brain tumors and approximately 50% of gliomas.

Gliomas

Gliomas are a class of tumor that develops from glial (neuroepithelial or support) cells. Astrocytes, ependymal, and oligodendroglial cells are all examples of glial cells that compose the supportive tissue of the brain. Gliomas comprise nearly one-half of primary brain tumors and one-fifth of all primary spinal cord tumors. Contemporary classification of gliomas is based on the World Health Organization (WHO) system, which classifies the tumors according to the cell of origin and histologic features identified by the pathologist. Grade I tumors are circumscribed lesions and may be potentially cured by complete resection. Therefore, these may be considered benign lesions. Grade II lesions are infiltrative lesions that might progress to become malignant, albeit with much slower progression than other more aggressive higher grade lesions. Thus, Grade II lesions are pathologically and clinically distinct from grade I lesions and should be considered potentially malignant. High grade gliomas grow much more quickly, and are assigned either a grade III (anaplastic) or IV (glioblastoma multiforme). Combined, grade III and IV gliomas account for approximately 40% of all primary brain tumors in patients aged 40-49 years, and 60% in patients older than 60 years. In most clinical series, grade III tumors represent approximately 10-15% of gliomas and grade IV constituting at least 30% of all primary brain tumors and approximately 50% of gliomas.

Malignant gliomas account for approximately 40% of the 17,000 primary brain tumors diagnosed annually in the United States. In Puerto Rico malignant gliomas account for 14% of all primary brain tumors intervened annually (46). Forty four thousand primary brain tumors were treated at Clínicas Las Américas, San Juan, PR. Malignant gliomas are one of the
most devastating tumors that can affect any given individual. Grade IV gliomas, or “GBM” have a mean survival time of less than 12 months with the best available treatment (47).

Current conventional treatment for malignant gliomas involves a combination of surgery, radiation, and chemotherapy. The prognosis of these patients remains poor. Historically, patients treated with surgery alone have median survival duration of less than 6 months. The addition of postoperative radiotherapy extended the median survival time to approximately 9 months. Efforts to increase radiation doses to the local tumor region have included new techniques such as radiosurgery (48) and brachytherapy, (49) which have also met with limited success. Kondziolka et al. (50) reported a survival benefit, but could not exclude selection bias as the cause, on 64 patients treated with gamma knife radiosurgery. The only radiosurgery randomized trial for malignant gliomas published, failed to show any benefit for patients with GBM who were treated with radiosurgery:48

At this time radiosurgery is reserved for patients as a salvage procedure in patients with enlarging malignant gliomas in good neurologic status when all other medical and surgical treatments have been employed.

Conclusion

Surgery still remains the gold standard for the treatment of most intracranial tumors. Nevertheless, patients may experience residual tumor or recurrence and therefore adjuvant treatment is recommended for these patients. Radiosurgery may even serve as a primary treatment for those patients deemed unfit for surgical removal because they have significant comorbidities or tumors in a surgically inaccessible location. More recently, stereotactic radiosurgery has been demonstrated to be a safe and highly effective for many of the tumors described previously. Furthermore, the complications rate associated with radiosurgery are low when compared to surgery. The indications for radiosurgery are expanding. With further sophistication of the radiosurgery treatment algorithm better results with fewer complications are expected in the future.

Resumen

La gran mayoría de las patologías intracraneales son tratadas mediante manejo médico, cirugía, radioterapia y recientemente, la radiocirugia estereotáctica. La radiocirugia estereotáctica se ha desarrollado hasta convertirse en un procedimiento neuroquirúrgico reconocido para el manejo de una amplia variedad de desórdenes intracraneales. La meta de este estudio es describir la experiencia en Puerto Rico con esta tecnología y reparar la eficacia, la seguridad y el papel de la radiocirugia en el tratamiento de los tumores intracraneales más comunes. Se revisó la casuística de pacientes tratados en Clínicas Las Américas, el primer centro en Puerto Rico en implementar esta tecnología y la base de datos de la literatura médica referente a radiocirugia estereotáctica realizada en las patologías intracraneales más comunes. Cada estudio fue examinado para determinar los parámetros neuroquirúrgicos, el seguimiento de los pacientes, el control del crecimiento del tumor y las complicaciones. Un total de 50 estudios fueron repasados. En tumores benignos se obtuvo un control del tamaño del tumor en el 90% de los pacientes. Desafortunadamente, para los tumores primarios cerebrales malignos el procedimiento no es curativo, pero ha sido eficaz en mejorar la supervivencia y la calidad de vida. Aunque la microcirugía sigue siendo la modalidad primaria de tratamiento de muchas lesiones intracraneales, la radiocirugía ofrece una alternativa complementaria segura y eficaz. Refinamientos en estas técnicas radiquirúrgicas probablemente conducirán a mejores resultados.

References


PRHSJ Vol. 29 No. 3 • September, 2010
46. Murray G., Jiménez L., Báez F, et al. Descriptive Profile of Surgically-con-